ATE56870T1 - Antibiotika. - Google Patents

Antibiotika.

Info

Publication number
ATE56870T1
ATE56870T1 AT86101308T AT86101308T ATE56870T1 AT E56870 T1 ATE56870 T1 AT E56870T1 AT 86101308 T AT86101308 T AT 86101308T AT 86101308 T AT86101308 T AT 86101308T AT E56870 T1 ATE56870 T1 AT E56870T1
Authority
AT
Austria
Prior art keywords
cefbuperazone
hemiacetonate
stable
arginine
free acid
Prior art date
Application number
AT86101308T
Other languages
English (en)
Inventor
Murray Arthur Kaplan
Robert Alan Lipper
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE56870T1 publication Critical patent/ATE56870T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT86101308T 1985-02-01 1986-01-31 Antibiotika. ATE56870T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69736285A 1985-02-01 1985-02-01
EP86101308A EP0189941B1 (de) 1985-02-01 1986-01-31 Antibiotika

Publications (1)

Publication Number Publication Date
ATE56870T1 true ATE56870T1 (de) 1990-10-15

Family

ID=24800837

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86101308T ATE56870T1 (de) 1985-02-01 1986-01-31 Antibiotika.

Country Status (5)

Country Link
EP (1) EP0189941B1 (de)
JP (1) JPS61180717A (de)
AT (1) ATE56870T1 (de)
CA (1) CA1242699A (de)
DE (1) DE3674422D1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63174927A (ja) * 1987-01-14 1988-07-19 Tanabe Seiyaku Co Ltd 抗菌性凍結乾燥製剤
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
NZ619413A (en) 2006-05-04 2015-08-28 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR20210033559A (ko) 2009-11-27 2021-03-26 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
CN101830916B (zh) * 2010-05-14 2013-08-14 胡梨芳 抗菌药物及其制备方法和用途
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102351885B (zh) * 2011-08-19 2012-08-22 深圳立健药业有限公司 用于制备头孢呋辛-l-精氨酸水合物的方法
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
EP2849755A1 (de) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH Xanthinderivat als dpp-4-hemmer zur verwendung bei der behandlung von durch podozyten vermittelten erkrankungen und/oder des nephrotischen syndroms
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
CN113069422B (zh) * 2021-04-20 2022-07-12 海南通用三洋药业有限公司 注射用头孢拉宗钠冻干粉针剂的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4054738A (en) * 1975-12-22 1977-10-18 Eli Lilly And Company Sodium cefamandole crystalline forms
US4237279A (en) * 1979-07-27 1980-12-02 Eli Lilly And Company Crystalline 3-hydroxycephalosporin solvates
IT1141406B (it) * 1980-04-01 1986-10-01 Dob Far Spa Sali della cefapirina con aminoacidi
EP0091502A1 (de) * 1982-04-13 1983-10-19 Asahi Kasei Kogyo Kabushiki Kaisha Pharmazeutisches Cephalosporinpräparat für rektale Verabreichung
US4458070A (en) * 1982-07-19 1984-07-03 Pfizer Inc. Process for the manufacture of crystalline sodium cefoperazone

Also Published As

Publication number Publication date
DE3674422D1 (de) 1990-10-31
EP0189941A2 (de) 1986-08-06
JPS61180717A (ja) 1986-08-13
EP0189941B1 (de) 1990-09-26
EP0189941A3 (en) 1987-08-19
CA1242699A (en) 1988-10-04

Similar Documents

Publication Publication Date Title
DE3674422D1 (de) Antibiotika.
NO169439C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive oxadiazoler
FI871750A (fi) Nasal administration av laekemedel.
NO863061D0 (no) Fremgangsmaate for fremstilling av fysiologisk aktive fenoksyeddiksyrederivater.
NO882732D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
NO864425L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocyklyl-oksoftalazinyl-eddiksyre-derivater
NO865204L (no) Fremgangsmaate for fremstilling av terapeutisk aktive benzosyre- og benzosyreester-derivater.
NO871295D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
ATE94765T1 (de) Pharmazeutische praeparate zur verbesserten resorption antibakterieller verbindungen.
NO871028D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazol- og oksazol-derivater.
NO870049D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
DE3875867D1 (de) Kalziumzusaetze.
NO863373D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminosyre derivater.
DE68901105D1 (de) Alkensaeurederivate.
TR20212A (tr) Stabilize azulmik asidler,imallerine mahsus usuller ve kullanilmalari
DE3685275D1 (de) Herstellung von 5-fluor-2'-deoxyuridin estern zur intravenoesen verabreichung.
NO884123L (no) Stabilisering av terapeutisk virksomme proteiner i farmasoeytiske preparater.
EP0189942A3 (en) Cefbuperazone crystalline triethylamine salt
NO883520L (no) Fremgangsmaate for fremstilling av et injeksjonspreparat.
NO172491C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,3-dioksan-alkensyre-dervater
BG60236B1 (bg) Метод за получаване на цикличен пропиленов естер на дихидропиридин-5-фосфонова киселина
DK576687A (da) Terapeutisk aktive alkensyrederivater
DK116687A (da) Farmaceutisk praeparat indeholdende aenovantroneae
IT1216233B (it) Utilizzazione della forma farmaceutica 'gel'contenente acido n (2,6 dicloro m tolil) antranilico (acido meclofenamico) impiegabile in terapia per uso topico.
NO168473C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenylthiazoloner.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee